Patent intelligence · US
US 7867171
Management of gastro-intestinal disorders
Management of gastro-intestinal disorders
Patent details — US 7867171
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 11, 2011
- Expiration
- Jan 6, 2031
- Applicant
- EXALENZ BIOSCIENCE LTD.
- Claims
- 49
- CPC classes
- A61K, A61K49/0004, A61K51/1206
Quick answer
US 7867171 (Management of gastro-intestinal disorders) is held by EXALENZ BIOSCIENCE LTD.. Status: granted. Granted Jan 11, 2011. Expires Jan 6, 2031 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- EXALENZ BIOSCIENCE LTD.
- Grant date
- Expiration
- Claims
- 49
- CPC classes
- A61K, A61K49/0004, A61K51/1206
More from EXALENZ BIOSCIENCE LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12414942
Compositions, methods, and systems for treating presbyopia
granted -
US 12180206
Aceclidine derivatives, compositions thereof and methods of use thereof
granted -
US 12128036
Compositions and methods for storage stable ophthalmic drugs
granted -
US 11648247
Compositions and methods for the treatment of presbyopia
granted -
US 11344538
Methods for the treatment of myopia
granted -
US 11273150
Compositions and methods for the treatment of presbyopia
granted -
US 11214569
Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof
granted -
US 11179328
Compositions and methods for the treatment of presbyopia
granted
Frequently asked questions
What is US patent 7867171?
US 7867171 (Management of gastro-intestinal disorders) is held by EXALENZ BIOSCIENCE LTD.. Status: granted. Granted Jan 11, 2011. Expires Jan 6, 2031 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7867171?
EXALENZ BIOSCIENCE LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 7867171 expire?
Our index shows an expiration date of Jan 6, 2031 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.